Ashish Lawankar, Nitin Sukadev Hivale and M.A. Momin
Page: 1-6 | Received 20 Nov 2025, Published online: 20 Jan 2026
Full Text Reference XML File PDF File
Venous and arterial thromboembolic complications affect around 16% of patients hospitalized with COVID‐19 and approximately 49% of patients with COVID‐19 in intensive care units (ICUs), with most patients being diagnosed with venous thromboembolism. COVID‐19 infection was more likely to have severe lymphopenia, elevated D‐dimer, ferritin, LDH. So, to overcome complication because of thromboembolic event, use of anticoagulant and antiplatelets has increased. To assess use of anticoagulant and antiplatelet drugs in covid‐19 infection. To analyze outcomes in relation to duration of hospital stay and mortality. This study was a retrospective observational study. Randomly selected 100 SARS‐CoV‐2 positive patients admitted to tertiary care hospital in January to June 2021 were taken as study population. Data had been collected and analyzed for association of covid‐19 infection and use of anticoagulant and antiplatelet drugs used. Out 100 patients of covid‐19, 52 were expired during treatment and 48 were cured. 52 patients who expired had more abnormal parameter like ferritin, LDH, CT score, SpO2 etc. These patients had less hospital stay with less days of anticoagulant and antiplatelets used as a treatment. Current study confirmed that if there is severe type of covid infection which spread to lungs and continuing to hypercoagulation is difficult to manage with drugs therapy like anticoagulants and antiplatelets.
Ashish Lawankar, Nitin Sukadev Hivale and M.A. Momin. Association of Use of Anticoagulant and Antiplatelet Drugs in Covid‐19 Infection and their Outcome in Relation to Duration of Hospital Stay and Mortality.
DOI: https://doi.org/10.36478/10.36478/makrjp.2026.1.1.6
URL: https://www.makhillpublications.co/view-article/1815-9362/10.36478/makrjp.2026.1.1.6